MACSF

COMMUNIQUÉS West-GlobeNewswire

Solera Health Unveils Enhanced AI Governance Framework for Responsible and Transparent Use of Artificial Intelligence in Digital Health
02/06/2025
Framework Sets an Industry Benchmark for Client Trust and Ethical AI Use to Ensure Patient Safety and Accountability PHOENIX, June 02, 2025 (GLOBE NEWSWIRE) -- Solera Health , the premier digital health delivery company [...]
Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
02/06/2025
TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy ORR is remarkably high in patients with no prior CAR-T or [...]
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
02/06/2025
MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive [...]
Liberation Labs is Now Liberation Bioindustries
02/06/2025
New name, new brand better reflects the company’s position as a global, commercial-scale biomanufacturer RICHMOND, Ind., June 02, 2025 (GLOBE NEWSWIRE) -- Liberation Labs has a new name and brand – Liberation [...]
PathAI and Northwestern Medicine Announce Strategic Collaboration to Deploy the AISight® Digital Pathology Platform and Co-Develop New AI Diagnostics
02/06/2025
Collaboration includes use of PathAI’s AISight®¹ digital pathology image management system at Northwestern Medicine and joint efforts in research, clinical innovation, and algorithm co-development to advance pathology- [...]
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression
02/06/2025
SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
02/06/2025
- Expert Insights on Clinical Relevance and Scientific Rationale - The replay of the event is available on the Investor Relations section of the Actuate website CHICAGO and FORT WORTH, Texas, June 02, 2025 (GLOBE [...]
TerrAscend Announces Chief Financial Officer Transition Plan
02/06/2025
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND, OTCQX: TSNDF) , a leading North American cannabis company, today announced that Keith Stauffer, Chief Financial [...]
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
02/06/2025
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
02/06/2025
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy Dyadic is well [...]
FDA expands XENOVIEW® indication to include children from six years of age
02/06/2025
Increases number of eligible patients by approximately one million DURHAM, NC and LONDON, June 02, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical [...]
SS Innovations to Ring the Nasdaq Opening Bell on Tuesday, June 3, 2025
02/06/2025
FORT LAUDERDALE, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making [...]
NewGen Announces Planned $30 Million Strategic Investment in Solana Digital Asset Staking
02/06/2025
NewGen’s significant expansion of its digital asset portfolio demonstrates its continued commitment to the blockchain technology sector BANGKOK, June 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF [...]
TELA Bio Appoints Jeffrey Blizard as President
02/06/2025
Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on [...]
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
02/06/2025
All dollar amounts reflected in Canadian dollars unless otherwise stated VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a [...]
Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025
02/06/2025
Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancer Final clinical data demonstrate an 87% overall response rate in patients with [...]
LogicMark, Inc. Common Stock to Commence Trading on OTC Markets as the Company Continues Advancing Growth Initiatives
02/06/2025
LOUISVILLE, Ky., June 02, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (the “Company”), a provider of personal emergency response systems (“PERS”), health communication devices, and technology for the growing care economy, [...]
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
02/06/2025
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy [...]
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
02/06/2025
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June 02 [...]

Pages